The calcium-sensing receptor as a regulator of cellular fate in normal and pathological conditions by Diez Fraile, Araceli et al.
Send Orders of Reprints at bspsaif@emirates.net.ae 
282 Current Molecular Medicine 2013, 13, 282-295  
 
 
The Calcium-Sensing Receptor as a Regulator of Cellular Fate in 
Normal and Pathological Conditions 
A. Diez-Fraile1, T. Lammens2, Y. Benoit2 and K.G.M.A. D’Herde*,1 
1
Department of Basic Medical Sciences, Ghent University, Faculty of Medicine and Health Sciences, 9000 
Ghent, Belgium 
2
Department of Pediatric Hematology-Oncology, Ghent University Hospital, 9000 Ghent, Belgium 
Abstract: The calcium-sensing receptor (CaSR) belongs to the evolutionarily conserved family of plasma 
membrane G protein-coupled receptors (GPCRs). Early studies identified an essential role for the CaSR in 
systemic calcium homeostasis through its ability to sense small changes in circulating calcium concentration 
and to couple this information to intracellular signaling pathways that influence parathyroid hormone secretion. 
However, the presence of CaSR protein in tissues is not directly involved in regulating mineral ion homeostasis 
points to a role for the CaSR in other cellular functions including the control of cellular proliferation, 
differentiation and apoptosis. This position at the crossroads of cellular fate designates the CaSR as an 
interesting study subject is likely to be involved in a variety of previously unconsidered human pathologies, 
including cancer, atherosclerosis and Alzheimer’s disease. Here, we will review the recent discoveries 
regarding the relevance of CaSR signaling in development and disease. Furthermore, we will discuss the 
rational for developing and using CaSR-based therapeutics. 
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1. INTRODUCTION 
 Brown and colleagues identified and cloned the 
calcium-sensing receptor (CaSR, also called GPRC2A) 
from bovine parathyroid cells in their quest to identify 
the calcium-sensing molecule responsible for coupling 
extracellular calcium concentration to parathyroid 
hormone (PTH) secretion [1]. The CaSR is an 
evolutionarily conserved G protein-coupled receptor 
(GPCR) highly expressed in tissues involved in 
systemic calcium homeostasis, including the 
parathyroid gland, calcitonin-secreting C cells of the 
thyroid gland, kidney, bone and gastrointestinal tract 
[2], where it contributes to maintenance of systemic 
calcium within a narrow physiological window. 
Activation of the parathyroid gland CaSR by increased 
levels of extracellular calcium suppresses PTH 
secretion, resulting in increased renal calcium excretion 
and decreased calcium resorption from bone tissue. In 
kidneys, CaSR activation can directly enhance urinary 
calcium excretion by inhibiting distal tubular calcium 
reabsorption, and in C cells, CaSR activation 
stimulates the release of calcitonin, inhibiting bone 
resorption and stimulating renal calcium excretion. 
 Recently, the CaSR was found to be widely 
expressed in cells and tissues not directly involved in 
systemic calcium homeostasis, as well. Not 
surprisingly, the CaSR works pleiotropically at multiple  
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levels, regulating diverse processes such as hormone 
secretion, gene expression, ion channel activity, 
inflammation, and control of cellular fate. Here, we will 
review the recent findings regarding the physiological 
effects of CaSR activity on the regulation of cellular 
fate, particularly in the context of proliferation, 
differentiation and apoptosis [2-10]. We will discuss 
how CaSR signaling determines cellular fate during 
normal development and how dysregulated signaling 
might promote the pathogenesis of many diseases, 
ranging from proliferative to neurodegenerative and 
vascular diseases. 
2. STRUCTURAL FEATURES 
 The CaSR is a member of a unique subfamily (known 
as family 3 or family C) of GPCRs which includes eight 
subtypes of metabotropic glutamate receptors (mGluR1–
8), two type B -aminobutyric acid receptors (GABABRs), 
the promiscuous L--amino acid receptor GPRC6A, three 
taste receptors, several pheromone receptors, and five 
orphan receptors [11]. The human CaSR gene is located 
on chromosome 3q13.3-21 and spans over 50 kb of 
genomic DNA. Its cDNA sequence predicts a 120-kDa 
protein, harbouring seven transmembrane (7TM)-span-
ning alpha-helices, a characteristic feature of all GPCRs. 
Other structural features include a large extracellular 
domain (ECD) in the N-terminal portion of the receptor 
defined by a Venus flytrap (VFT) module and a cysteine-
rich domain, and an intracellular carboxyl terminal tail with 
consensus regulatory phosphorylation sites for protein 
kinase C (PKC) and protein kinase A [12]. Apart from 
phosphorylation, the CaSR can undergo several other 
post-translational modifications including intermolecular 
disulphide homodimerization and glycosylation of its 
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extracellular domain, evidenced by 11 potential N-
glycosylation sites in its extracellular N-terminus [13]. 
Several observations show that these modifications might 
be essential for CaSR expression and/or function. 
Specifically, glycosylation and dimerization appear to be 
essential for proper folding and trafficking of the CaSR 
protein, eventually regulating the membrane expression 
of the CaSR. Moreover, an altered CaSR glycosylation 
pattern has been observed in some forms of familial 
hypocalciuric hypercalcemia (FHH) [14]. 
3. REGULATION OF CASR EXPRESSION 
3.1. Transcriptional Regulation 
 During recent years, it has become clear that CaSR 
expression depends on the cell or organ type, 
developmental state and even extracellular conditions. 
Although the promoter and untranslated regions of the 
CaSR have been characterized, only a few regulatory 
regions have been linked to the varied expression. Suzuki 
et al. characterized the presence of a thyroid transcription 
factor 1 (TTF1)-binding site in the 5’ flanking region of the 
CaSR, and found that TTF1 directly regulates CaSR 
transcription in cell types co-expressing TTF1 and CaSR 
(this includes parathyroid cells, neural cells in the anterior 
pituitary or hippocampus, and keratinocytes, but excludes 
cells such as buffalo rat liver cells) [15]. However, the 
authors demonstrated that this regulation might be more 
complicated than anticipated since TTF1 levels depend 
on internal calcium concentration, as well [15]. Further 
analysis of potential transcription factor (TF)-binding sites 
within the proposed CaSR promoter indicates the 
presence of two binding regions for EBF1 and one 
binding region each for NF-B, BATF, c-Jun, BAF-155, 
FOSL2 and BCL11A (Fig. 1). The well-established role of 
these TFs in regulating cellular fate establishes the 
transcriptional platform for the involvement of CaSR 
signaling in regulating proliferation, differentiation and 
apoptosis. Thus, it will be of great interest to assess 
whether one or several of these TFs regulate CaSR 
mRNA levels. 
 Several vitamin D response elements have been 
identified in the CaSR promoter, as well (Fig. 1). A 
study by Abukawa et al. revealed that the vitamin D-
dependent regulation of CaSR expression is tissue-
specific [16]. In this study, the authors showed that 
vitamin D positively regulates CaSR transcript levels in 
rat kidney but does not affect CaSR mRNA expression 
levels in intestine or calvaria. However, whether this 
differential expression correlated with a loss of vitamin 
D-responsive elements, which is suggested by the 
different transcript lengths observed in the respective 
tissues, remains to be determined [16]. 
3.2. Splice Variants 
 In addition to differential TF-binding, an extra level 
of gene regulation is generated by differential splicing. 
Oda et al. identified the presence of an exon-5-less 
CaSR transcript in human keratinocytes and made two 
crucial observations related to CaSR function [17]. 
First, they observed that the splice variant possesses 
an altered glycosylation pattern and is unable to 
mediate the acute response to extracellular calcium in 
keratinocytes. Second, they found that the full-length 
CaSR transcript is expressed predominantly in 
undifferentiated keratinocytes, and expression levels 
decrease as the cells differentiate. In contrast, the 
exon-5-less splice variant transcript is expressed 
throughout keratinocyte differentiation [17]. Thus, the 
expression of a CaSR splice variant that does not 
respond to calcium points to additional functions of the 
CaSR outside of calcium homeostasis. This exon-5-
less transcript has been found in the growth plate and 
kidney of mice [18, 19], as well, and an exon-3-less 
transcript has been reported to be expressed in 
cytotrophoblasts of human placenta [20]. This exon-3-
less splice variant encodes a truncated protein of 153 
amino acids, which would not be incorporated into the 
plasma membrane. As described for truncated forms of 
other receptors, it might be released into the 
extracellular fluid (circulation), but to the best of our 
knowledge nobody has reported on the functional 
significance of this [20, 21]. 
 Wang et al. have shown that rat dorsal root ganglion 
neurons express a CaSR transcript that differs from the 
classical transcript (which they define as being 
expressed in the thyro-parathyroid and kidney) in the 5’ 
untranslated region (5’UTR) due to splicing of 
alternative exons into a common coding region [22]. 
This fits the earlier observation of this variant in the 
human system by Chikatsu and colleagues [23]. It is 
well-established that the 5’UTR contains elements that 
regulate the stability and translation of the 
corresponding transcript, but the impact of this 
alternatively spliced 5’UTR on CaSR expression has 
not been assessed. 
3.3. MicroRNAs 
 Small non-coding microRNAs (miRNAs) emerged 
recently as novel regulators of gene expression. 
MicroRNAs function through complementary base-
pairing with target mRNAs, subsequently leading to the 
inhibition of translation or to degradation of the mRNA 
target. MicroRNAs have been shown to be involved in 
virtually all cellular processes and are frequently 
dysregulated in disease states including cancer. 
Although several miRNAs are predicted to bind the 
CaSR mRNA and potentially regulate CaSR expression 
(our unpublished observations), to our best knowledge, 
none has been confirmed to regulate CaSR (Fig. 1). 
 Several post-transcriptional mechanisms, including 
ubiquitination, homodimerization and m-calpain-
dependent destruction, regulate CaSR protein levels, 
as well, and these will be discussed in more detail in 
‘Signaling and binding partners’ below. 
4. SIGNALING AND BINDING PARTNERS 
4.1. Positive and Negative Modulators 
 In contrast to what its name suggests, the CaSR 
has a broad spectrum of ligands, including its 
namesake calcium. Agents altering CaSR signaling are 
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generally divided into positive or negative modulators 
and orthosteric or allosteric ligands (which refers to the 
site of interaction). As such, we recognize orthosteric 
modulators, positive allosteric modulators and negative 
allosteric modulators (Fig. 2). Orthosteric modulators of 
the CaSR include calcium and other di- and trivalent 
cations (Be
2+
, Sr
2+
, Mg
2+
, Gd
3+
, La
3+
, Ba
2+
) that bind at 
the orthosteric site within the VFT module. In addition, 
polyamines, such as spermine, spermidine and 
putrescine, aminoglycoside antibiotics such as 
neomycin, and -amyloid peptides have been found to 
bind the orthosteric site [24-26]. In contrast, allosteric 
modulators bind outside of the orthosteric site, most 
likely changing the three-dimensional receptor 
conformation and, thus, affecting the receptor affinity 
and/or ligand-binding efficacy. Well-known natural 
allosteric activators include L-amino acids, which bind 
adjacent to the orthosteric site within the VFT module 
[27-29]. This ability of amino acids to regulate CaSR 
activation suggests the existence of a close link 
between calcium signaling and nutritional status. In 
recent years, several pharmacological agents that 
positively modulate CaSR signaling (calcimimetics) or 
negatively modulate CaSR signaling (calcilytics) have 
been developed. Both types of modulators bind the 
7TM extracellular loops of the CaSR [30]. These will be 
discussed in more detail in the section entitled “CaSR 
as a therapeutic target”. 
4.2. Receptor Dimerization 
 It is now well-accepted that the CaSR functions 
primarily as a homodimer supported by both covalent 
and non-covalent interactions [31]. Dimerization of the 
CaSR seems essential, but not sufficient, for 
membrane trafficking, and crucial for correct function 
[32, 33]. Besides homodimerization, the CaSR also 
forms heterodimers with other members of family C of  
 
the GPCR superfamily, such as mGluRs and 
GABABRs. Co-immunoprecipitation experiments 
revealed direct interactions of the CaSR with the 
mGluR1, GABABR1 and GABABR2 in certain regions 
of bovine and rat brains [34, 35]. These interactions 
have been shown to be determinative for both total 
cellular and cell surface expression of CaSR and the 
activation status of phospholipase C (PLC) [35]. 
Remarkably, while coexpression of the CaSR with 
GABABR1 reduced CaSR-dependent PLC activation, 
coexpression with GABABR2 increased agonist-
dependent PLC activation [35]. 
 In addition to direct interactions with other 
receptors, several research groups have demonstrated 
communication between the CaSR and the epidermal 
growth factor receptor (EGFR) [3, 36, 37]. Using a 
combination of inhibitors and neutralizing antibodies, 
Yano et al. showed that phosphorylation of extracellular 
signal-regulated kinase (ERK), a key target of CaSR 
signaling, could be abrogated by inhibiting the EGFR or 
the production of EGF through matrix metalloproteases 
in HEK293 cells stably expressing the CaSR (Fig. 2) 
[36]. Importantly, Haini and colleagues recently 
demonstrated the critical role of this CaSR-EGFR-ERK 
axis in the delivery of mitogenic signals in MCF7 breast 
cancer cells. Considering the function of EGFR in 
stimulating DNA synthesis and cell proliferation, this 
relationship connects the CaSR to determination of cell 
fate [37]. 
4.3. Protein Binding Partners 
 Recent reports demonstrate the interaction of CaSR 
with several other proteins. Using the intracellular tail of 
the CaSR as the bait in yeast two-hybrid screens, two 
groups independently identified the scaffold protein, 
filamin A, as a CaSR-binding partner. Such interactions 
with filamin A are believed to modulate the rates of  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Regulation of CaSR expression. TTF1 and vitamin D binding elements (green boxes) have been well-characterized in 
the 5’ flanking region and promoter, respectively, of CaSR. Potential transcription factor-binding sites, as reported in the UCSC 
genome browser (http://genome.ucsc.edu/) are depicted as well (blue box). Possible miRNA – CaSR mRNA interactions were 
determined using miRDB, miRanda and Targetscan prediction software, and the intersection is represented in the green box. 
miR: microRNA: RNA pol II: RNA polymerase II. 
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Fig. (2). Schematic diagram of CaSR signaling and interaction partners. A. CaSR interaction partners are commonly 
categorized as orthosteric modulators, positive allosteric modulators or negative allosteric modulators. B. The CaSR is present 
on the cell membrane as a homo- or heterodimer, and affects the signaling of other receptors such as EGFR (shown here; see 
text for other CaSR partners). The signaling cascades initiated by the CaSR include (but are not limited to): Gi-dependent 
inhibition of adenylate cyclase (AC), reducing cyclic AMP (cAMP) production; interaction with filamin A and Rho, regulating cell 
adherence through E-cadherin; Gq-dependent activation of cytosolic phospholipase A2 (cPLA2), causing the accumulation of 
arachidonic acid (AA); Gq-mediated activation of phospholipase C (PLC), activating protein kinase C (PKC) through 
diacylglycerol (DAG) and the release of calcium from the endoplasmic reticulum through inositol 1,4,5-trisphosphate (IP3); 
activation of mitogen-activated protein kinases (MAPK) such as JNK and p38; and Gq-dependent activation of epidermal 
growth factor (EGF)-signaling, resulting the activation of the Ras-Raf-MEK-ERK signaling cascade. The complex array of CaSR-
regulated pathways ultimately result in the regulation of gene transcription for proliferation and survival, regulation of parathyroid 
hormone (PTH) secretion and synthesis, regulation of parathyroid hormone-related protein (PTHrP) secretion and the regulation 
of cell adherence through E-cadherin. 
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receptor desensitization and degradation. Notably, 
inhibition of CaSR expression with antisense cDNA 48 
hours after transfection with or without filamin A 
resulted in a lower level of CaSR expression in cells 
without filamin A, suggesting that filamin A protects the 
CaSR from degradation [38]. Several other groups 
have provided evidence that the interaction with filamin 
A is, at least partially, involved in the CaSR-dependent 
activation of downstream mitogen-activated protein 
kinases (MAPKs) and Rho, a Ras-like family member 
involved in many cellular functions including 
proliferation (Fig. 2) [39, 40]. 
 In addition to filamin A, the potassium channel 
Kir4.2 was identified as a potential CaSR-binding 
partner. Given the interaction of Kir2.1 with filamin A, 
the authors postulated that filamin A might act as a 
scaffold, bringing the CaSR and Kir4.2 together [41]. 
With the addition of Dorfin to the list of CaSR-binding 
partners, it became clear that the CaSR protein levels 
are, at least partially, regulated through a general 
mechanism of poly-ubiquitination [42]. Kifor and 
colleagues identified the CaSR protein to be sensitive 
for m-calpain-dependent destruction, as well, adding an 
additional mechanism for regulating CaSR protein 
expression [43]. 
4.4. Intracellular Signaling 
 The intracellular signaling of CaSR has been the 
subject of intense investigation (Fig. 2). Reports using 
overexpression, knock-down or pharmacological 
inhibition or stimulation of CaSR signaling have 
provided clear evidence for a role of CaSR in fine-
tuning proliferation, differentiation and apoptosis. As is 
the case with many other cell-surface receptors, at 
present, it is only poorly understood how the activation 
of a single receptor type, in this case the CaSR, can 
result in such varied biological endpoints. 
 Generally, ligand binding to the CaSR results in the 
activation of PLC in a Gq-mediated manner (Gq: 
subunit of heterotrimeric G protein). Subsequently, PLC 
propagates this signal using multiple signaling 
pathways (Fig. 2). The accumulation of inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) observed 
upon CaSR stimulation was shown to depend on PLC 
activation, since this IP3 response could be blocked by 
the PLC inhibitor U-73122 [44]. In turn, IP3 induces the 
release of intracellular calcium from the endoplasmic 
reticulum, resulting the activation of cytosolic 
phospholipase A2 (cPLA2) and the generation of 
second messengers such as arachidonic acid (Fig. 2). 
In kidney, this cPLA2 signaling axis mediates the 
effects of hypercalcemia (see: CaSR in development). 
 The release of DAG, in addition to the increased 
cytoplasmic calcium concentration, activates PKC (Fig. 
2) [45, 46]. Activated PKC serves as an input signal for 
MAPK cascades, controlling cell proliferation and 
apoptosis. Using inhibitor studies, Kifor et al. 
demonstrated that activation of PKC in the CaSR-PLC 
axis results in phosphorylation (activation) of ERKs 
through MAPK kinases (MEKs) [47]. Almost 
simultaneously, Hobson and colleagues identified two 
additional pathways through which CaSR activation 
stimulates ERK phosphorylation. In an elegant study 
using rat ovarian epithelial cells as a model, Hobson 
and colleagues identified the CaSR-Src-Ras-Raf-MEK-
ERK pathway as a CaSR-driven alternative path to 
ERK activation (Fig. 2) [48]. Later, the same authors 
implicated phosphatidylinositol 3-kinase (PI3K) in 
CaSR-dependent ERK activation, driven by the 
observation that only low levels of ERK activation were 
detected after treatment of CaSR-stimulated ovarian 
epithelial cells with PI3K inhibitors. Importantly, in this 
study, they observed that ERK activation can be 
blocked by tyrosine kinase inhibitors in Rat-1 
fibroblasts, whereas this was not the case in CaSR-
transfected HEK293 cells. Although in vitro, this work 
illustrates that, at least to some extent, the specific 
CaSR downstream signaling pathways are cell-type 
specific, explaining the differential readouts in various 
cell types examined [49]. Further studies have 
implicated JNK and p38 MAPK in CaSR-stimulated 
pathways involved in proliferation and apoptosis, as 
well (Fig. 2) [50-52]. 
 Generally, the activation of MAPK cascades serves 
to control cell survival and proliferation through multiple 
distal effectors. Indeed, in many instances, activation of 
the CaSR results in the transcription of mRNA for Fos, 
Egr-1 and cyclin-D [53], all of which help promote the 
G1/S cell cycle transition [53]. Several reports witness 
that CaSR-mediated apoptosis, through mechanisms 
related with calcium overload and activation of the 
mitochondrial apoptotic pathways, involves the 
downregulation of Bcl-2 expression, and upregulation 
of caspase-3, cytochrome c and Fas/FasL expression 
[54-59]. Importantly, Mentaverri et al. reported that NF-
B activation, which promotes expression of cell death 
genes such as p53, c-Myc and Bcl-xS, is a downstream 
effect of CaSR stimulation in mature rabbit osteoclasts 
[60]. Phosphorylation of ERK regulates cell growth and 
differentiation through phosphorylation and activation of 
nuclear TFs, such as Elk-1. In agreement with these 
downstream effects, stimulation of the CaSR in many 
model systems, including smooth muscle cells, 
epithelial cells and granulosa cells, results in an 
increased cell number and/or increased survival [5, 10, 
49, 53, 61]. Finally, CaSR signaling also has been 
implicated in regulating colonic epithelial cell 
differentiation and keratinocyte differentiation through 
the activation of E-cadherin signaling in a Rho-
dependent manner with filamin A involvement (Fig. 2) 
[62-64]. Chakrabarty and colleagues demonstrated that 
stimulation of the CaSR through extracellular calcium 
increased the expression of the tumor suppressor on 
colon carcinoma cells, and concomitantly reduced the 
activation of -catenin/T-cell factor, leading to the 
suppression of their malignant behavior [63]. They 
concluded that, consequently, the integrity of the 
CaSR-E-cadherin--catenin axis may be important in 
maintaining correct colon epithelial cell differentiation 
[63]. In addition, keratinocyte differentiation has been 
shown to depend on the physical interaction between 
the CaSR, filamin A and Rho. Moreover, the Rho-
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filamin axis would drive a diverse array of kinase 
activities [64, 65]. 
 In addition to this already highly complex signaling 
network, calcium-stimulation of the CaSR 
downregulates cellular cyclic AMP (cAMP) levels 
through adenylate cyclase (AC) in a Gi-dependent 
mechanism [66]. Lower levels of cAMP eventually 
result in decreased secretion of the PTH-related protein 
(PTHrP), which, among others, is involved in bone and 
teeth development [66]. Interestingly, Mamillapalli and 
colleagues have provided evidence that the alternative 
use of the Gs subunit stimulates AC activity and, thus, 
cAMP production [67]. 
5. DIFFERENTIAL TISSUE EXPRESSION AND 
REGULATION OF CELLULAR FATE 
5.1. Fetal Development 
 The CaSR is highly expressed in the developing 
fetus, with the highest expression levels found in the 
central and peripheral nervous system, heart, lung and 
cartilage [68]. The developing fetus is hypercalcemic 
compared with the adult, with significantly higher levels 
of extracellular calcium found in cord blood as 
compared with maternal blood [69]. The elevated levels 
of extracellular calcium in the fetus appear necessary 
for proper fetal growth and development. Indeed, 
activation of the CaSR by high extracellular calcium or 
a calcimimetic was shown to promote axonal growth in 
murine fetal sympathetic neurons during the perinatal 
period. In addition, the CaSR plays a crucial role in the 
elaboration of normal dendritic arbors in pyramidal 
neurons during early postnatal development of the 
mouse hippocampus [70]. Regarding the developing 
mouse lung, Finney and colleagues demonstrated that, 
between embryonic days 10.5 and 16.5, calcium 
concentrations similar to those encountered in 
developing fetuses (~1.7 mM) inhibit lung branching 
morphogenesis and cellular proliferation while 
promoting lung fluid secretion via activation of the 
CaSR [71]. After embryonic day 16.5, CaSR 
expression progressively diminishes and is absent in 
adult lung tissue [1, 71, 72]. By means of tissue-
specific deletion of the CaSR, it was evidenced that 
CaSR expression is crucial for the proper fetal bone 
development and mineralization [73]. The CaSR is also 
expressed in fetal embryonic tissue of the placenta 
throughout pregnancy. It has been proposed that, in 
addition to the local control of transplacental calcium 
[74], the CaSR might contribute to the regulation of 
placental development, as well [75, 76]. 
5.2. Adult 
 In the adult, CaSR expression has been detected in 
a myriad of cells and tissues. By means of a short 
expression survey using Genevestigator 
(www.genevestigator.com), we confirm expression of 
the CaSR gene in a broad array of human adult tissues 
with varying degrees of abundance (Fig. 3). Expression 
of CaSR protein has been detected and implicated in 
regulating cellular fate in adult tissues including the 
parathyroid gland, bone, kidney and blood, as well as 
reproductive, cardiovascular, gastrointestinal and skin 
tissue. 
 The parathyroid gland expresses the highest levels 
of CaSR and CaSR activity within parathyroid cells may 
regulate cell survival [77]. Calcimimetic-treated uremic 
rats were shown to have smaller parathyroid glands, 
and increased apoptosis was observed in parathyroid 
cells in vitro [78]. However, two other reports using the 
same rat model did not detect an increase in the 
number of apoptotic parathyroid cells [79, 80]. The fast 
clearance of apoptotic cells by macrophages in vivo 
may hamper the visualization of dying cells and might 
explain this apparent contradiction. 
 Pronounced expression of the CaSR is also 
detected in the cardiovascular system, especially in 
heart tissue (Fig. 3). Activation of the CaSR can induce 
apoptosis in normal rat neonatal cardiomyocytes [54, 
81] and in cultured neonatal rat ventricular 
cardiomyocytes exposed to ischemia/reperfusion [55, 
82-84]. In addition, stimulation of CaSR with 
extracellular calcium in human aortic vascular smooth 
muscle cells has been shown to lead to cell 
proliferation and protection against apoptosis [5]. 
 Similarly, activation of CaSR in cultured osteoblasts 
treated with elevated concentrations of extracellular 
calcium not only promoted the proliferation of these 
cells but also stimulated cell differentiation and 
mineralization within bone tissue [53]. In the rat kidney, 
the calcimimetic R-568 exerts a direct nephroprotective 
action at the glomerular podocyte level, since this 
pharmacological activation of the CaSR limited 
podocyte damage through stimulation of anti-apoptotic 
and cytoskeleton-stabilizing mechanisms [85]. 
Pharmacologic modulation of the CaSR by cinacalcet, 
a positive allosteric modulator, enhances primitive 
hematopoietic cell activity in vitro, including growth in 
stromal cell cocultures [86]. 
 Within the human female reproductive tract, ovarian 
surface epithelial cells have been shown to express the 
CaSR [48]. Using immortalized ovarian surface 
epithelial cells, it was shown that the presence of 
increased extracellular calcium or the expression of a 
dominant negative mutant of the CaSR stimulates 
proliferation. The increased extracellular calcium 
concentration within this experimental setup mimics the 
higher local concentrations of calcium at the ovarian 
surface found upon ovulation. Thus, these results 
indicate that the CaSR might be involved in healing of 
the ruptured ovarian surface epithelium during 
ovulation [48, 87]. Before conception, the CaSR may 
play a role in oocyte meiotic maturation. Incubation of 
horse oocytes in the presence of calcium in 
combination with the calcimimetic R-467 results in 
significantly increased numbers of oocytes in 
metaphase II, and this is attenuated by pre-treatment 
with the CaSR antagonist NPS-2390 [88]. Furthermore, 
the CaSR is not only expressed in the germ line, but 
also in the surrounding somatic cells where activation 
has been proposed to play a role in follicle survival [10]. 
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 The CaSR is also widely expressed along the 
mammalian gastrointestinal tract including stomach, 
small intestine, and colonic mucosal epithelia, along 
with the underlying neural plexuses of Meissner and 
Auerbach [89]. In the intestine, although the relative 
expression of CaSR in colonic cells is below the mean 
(Fig. 3), studies carried out during the last decade have 
demonstrated that a functional CaSR is involved in the 
regulation of many aspects of colonic function, 
including the maintenance of epithelial proliferation, 
differentiation and development [89]. 
 A similar role has been described in skin epithelial 
cells, where activation of the CaSR has been reported 
to enhance cell differentiation and integrity in both 
mouse and human keratinocytes. In vitro, keratinocytes 
are extremely sensitive to variations in extracellular 
calcium, with low extracellular calcium promoting 
proliferation and extracellular calcium concentrations 
above 0.1 mM promoting differentiation [90, 91]. In 
agreement, Tu and colleagues have demonstrated that, 
in epidermal keratinocytes, CaSR activation by 
extracellular calcium and calcimimetics suppresses 
proliferation and increases the expression of genes 
involved in differentiation [92]. In vivo, the epidermis of 
full-length CaSR knock-out mice is thinner, abnormally 
flattened and less differentiated than that of wild-type 
animals [19]. In contrast, CaSR overexpression in the 
epidermis stimulates hair follicle formation and 
enhances epithelial integrity and the expression of 
differentiation markers [19, 92]. 
 In summary, several fetal tissues show a transient 
increase in CaSR expression within a precise 
developmental time window, during which CaSR has 
been suggested to contribute to cell differentiation and 
survival. In addition, activation of the extracellular 
CaSR in adults drives cellular fate by either inhibiting or 
stimulating proliferation, differentiation or apoptosis, 
depending on the tissue or cell type. 
6. CaSR IN HUMAN DISEASES 
 The identification of CaSR mutations fueled 
research into the involvement of the CaSR in human 
disease. To date, a massive repertoire of 257 CaSR 
mutations has been characterized (listen on 
http://www.casrdb.mcgill.ca/). The spectrum of 
mutations is diverse and includes large aberrations 
such as insertions and deletions, as well as smaller 
aberrations such as point mutations that create novel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Relative CaSR expression levels in different organs/tissues. Normalized expression data were obtained through 
Genevestigator (http://www.genevestigator.com). Obtained values were mean centered and ranked from high to low expression. 
CNS: central nervous system; PNS: peripheral nervous system. 
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splice sites, premature stop codons and single amino-
acid changes [93]. Furthermore, single nucleotide 
polymorphisms (SNPs) have been described [94-96]. 
None of the SNPs appears to cause disease directly, 
but rather to enhance predisposition to disease. In 
addition to sequence changes, autoantibodies against 
the CaSR have been detected in patients [97, 98]. 
Below, we will review the involvement of CaSR in 
cancer, Alzheimer’s disease and atherosclerosis. 
6.1. Cancer 
 Since the CaSR is involved in balancing cell 
proliferation and apoptosis in many tissues, it is no 
surprise that dysregulation of the CaSR might favor 
progression to cancer. CaSR signaling has now been 
implicated in the development of several cancer types, 
including colon cancer, prostate cancer, breast cancer 
and lung cancer [99]. Whether the CaSR behaves as 
an oncogene or a tumor suppressor seems dependent 
on the tissue involved and/or the stage of disease (i.e. 
metastatic involvement). 
 The involvement of CaSR in colorectal cancer has 
been studied extensively. In healthy colon, a calcium 
concentration gradient is maintained within the colonic 
crypts, with the highest concentrations found towards 
the luminal end of the crypt where cells undergo 
terminal differentiation and, ultimately, apoptosis, and 
the lowest levels found at the base of the crypts where 
cells actively divide [100]. CaSR expression is reduced 
or absent in many colon cancers, leading to 
uncontrolled growth in vitro [26, 101]. This suggests a 
tumor suppressor role for CaSR. Bhagavathula and 
colleagues have provided evidence that CaSR-
mediated stimulation of E-cadherin signaling is 
disturbed in colon carcinoma cells with low or absent 
CaSR expression, resulting in the inability to generate 
strong cell-cell adhesion and differentiation signals 
[102]. This reinforces the observation by Chakrabarty 
and colleagues who provided clear evidence that 
interfering with the CaSR-E-cadherin-catenin axis 
results in abnormal differentiation and/or malignant 
progression of colon epithelial cells [63]. In addition, 
several CaSR SNPs have been found to correlate with 
susceptibility to colon cancer and/or disease 
progression [95, 103-105]. 
 In the context of breast and prostate cancers (also 
called hypercalcemic cancers), CaSR activation 
promotes cancer progression and may favor 
metastases by stimulating tumor secretion of PTHrP 
[106-109]. PTHrP is a peptide growth factor that binds 
the same receptor as PTH, thereby activating bone 
turnover and, hence, contributing to the pathogenesis 
of cancers by promoting osteolytic bone destruction 
with release of bone-derived growth promoting factors. 
The local hypercalcemia generated through bone 
resorption further stimulates the CaSR, producing a 
vicious cycle [106, 108, 109]. In sharp contrast, Li et al. 
reported that activation of the CaSR by calcimimetics in 
metastatic prostate cancer cell lines promoted 
apoptotic cell death [56]. These differences may result 
from a modified downstream CaSR signaling network 
upon acquiring a metastatic phenotype, and future 
studies will be needed to clarify this issue. Recently, 
Huang and colleagues demonstrated that CaSR driven 
Rho signaling is an important regulator of cell 
proliferation in more tumorigenic prostate cancer cell 
lines [110]. 
 In addition to regulating tumorigenesis, CaSR 
expression levels have been found useful for risk 
stratification. Although investigated in a rather small 
cohort, elevated CaSR expression in breast tumors 
was reported to correlate with the incidence of bone 
metastasis [111]. This information suggests that the 
level of CaSR expression should be considered as a 
biomarker for the potential involvement of bone 
metastasis in breast cancer. 
 In hyperplastic parathyroid cells, CaSR activation by 
the calcimimetic R-568 induces apoptotic cell death, 
suggesting that in this specific tissue the CaSR 
functions as a tumor suppressor [57]. In accordance 
with the latter, CaSR expression is decreased in both 
parathyroid adenoma and hyperplasia [112]. Patients 
with inactivating mutations in the CaSR, especially 
those homozygous for such mutations, are prone to 
develop parathyroid hyperplasia. In contrast, no CaSR 
mutations were found in parathyroid tumors, but it was 
shown that the untranslated exon 1A is expressed to a 
lower extent as compared with normal parathyroid cells 
[26]. 
6.2. Alzheimer’s Disease (AD) 
 AD is characterized by a disturbance in calcium 
homeostasis in the brain, suggesting that dysregulation 
of CaSR signaling is likely to be involved in the 
development or progression of this disease. Indeed, 
Conley and colleagues identified a significant 
association between the length of a dinucleotide repeat 
within intron 4 (short versus long) of the CaSR and 
susceptibility to AD. It is noteworthy that this 
association was significant only for individuals without 
an APOE4 allele, a genotype considered to be an 
independent risk factor for the development of AD [113, 
114]. Furthermore, the authors provide evidence that -
amyloid peptides and apoE protein activate CaSR 
signaling in cell culture, enhancing intracellular calcium 
levels and further promoting dysregulation of calcium 
homeostasis and calcium-dependent -amyloid 
aggregation. In a more detailed analysis, Chairini and 
colleagues showed that -amyloid-dependent CaSR 
activation in astrocytes stimulates MAPK cascades and 
induces a massive release of nitric oxide, which either 
independently or through conversion to peroxynitrite 
damages neighboring neurons [115]. 
6.3. Atherosclerosis 
 Atherosclerosis is the primary cause of heart 
disease and stroke, and represents a major cause of 
the high cardiovascular mortality rate in patients with 
end-stage renal disease [116-118]. Vascular 
calcification is an active, regulated process similar to 
that of osteogenesis in bone. During this process, loss 
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of CaSR expression in vascular smooth muscle cells 
leads to the acquisition of an osteoblast-like phenotype 
and contributes to the generation of calcified nodules 
[119-123]. Koleganova and colleagues demonstrated, 
using an in vivo rat model for interstitial fibrosis and 
microvascular disease of the heart in uremia, that this 
transdifferentiation could be significantly delayed by 
administration of the calcimimetic R-568, suggesting 
the involvement of the CaSR in this process [124]. 
7. CaSR AS A THERAPEUTIC TARGET 
 The observed dysregulation of CaSR expression in 
hyperparathyroidism, a very common endocrine 
disease, and the change in clinical presentation of the 
disease following therapeutic targeting of the CaSR, as 
initially reported by Silverberg and colleagues [125], 
stimulated the development of CaSR-targeted drugs. 
Pharmacological agents with different modes of action, 
including allosteric modulators and monoclonal 
antibodies, are currently in development. 
7.1. Positive Allosteric Modulators 
 Currently, only one positive allosteric modulator of 
CaSR, cinacalcet (Mimpara
®
 in Europe; Sensipar
®
 in 
the USA), has entered the drug market [126]. 
Cinacalcet is used to increase CaSR activation, 
resulting in reduced PTH secretion and calcium levels 
in blood. Cinacalcet is currently prescribed for the 
treatment of secondary hyperparathyroidism in patients 
on dialysis for end-stage renal disease, and the 
treatment of primary hyperparathyroidism in patients 
with parathyroid carcinoma [126]. In addition to the 
conditions for which cinacalcet has been approved, 
literature indicates that this drug could be useful for 
treating other forms of primary and secondary 
hyperparathyroidism, as well as phosphate-wasting 
disorders, and may provide benefits in both infants and 
adults [126]. 
 Although not yet approved for retail markets, 
modulation of CaSR function by pharmacological 
agonists may have additional therapeutic potential for 
the treatment of disorders such as idiopathic 
generalized epilepsies due to rare missense CaSR 
variants [127]. CaSR agonists may be useful in treating 
hypertensive states characterized by an inappropriately 
elevated renin concentration, as well, and may 
constitute a new approach for the prevention and 
treatment of numerous kidney disorders, such as 
diabetic nephropathy, through the above-mentioned 
nephroprotective effects [85]. Furthermore, 
calcimimetics could be useful in bone marrow 
transplants for stimulating homing, lodging, and 
engraftment of transplanted hematopoietic stem cells 
and progenitor cells [86, 128]. In addition, it has been 
proposed that calcimimetics have the potential to be 
effective therapeutic agents for secretory diarrheas 
because of their ability to reduce cAMP-mediated fluid 
secretion by the colon in rats [129]. Since calcimimetics 
have been shown to reduce the parathyroid gland 
volume in rats, mice and humans [79, 80, 130, 131], 
these compounds may also be useful as 
antiproliferative drugs in other tissues. 
7.2. Negative Allosteric Modulators 
 Negative allosteric modulators (or calcilytics) of the 
CaSR have been developed as therapeutics for 
increasing bone growth by decreasing CaSR activation 
at the parathyroid gland and, thereby, stimulating 
endogenous PTH secretion. Such negative allosteric 
compounds are being studied for their potential use as 
anabolic agents in the treatment of osteoporosis [132]. 
Recently, it was shown in an ovariectomized rat model 
of bone loss that daily oral administration of the 
calcilytic prodrug SB-423557 increased bone formation 
and bone strength without affecting parathyroid cell 
proliferation [133]. Moreover, in aged female rats, the 
ATF936 calcilytic drug induced increased bone 
formation and, in healthy humans, a single dose 
triggered peak PTH levels and was well-tolerated [134]. 
However, further clinical studies will be needed to 
validate the efficacy and safety of ATF936 in treating 
osteoporosis. In addition, calcilytics could be useful for 
correcting hypocalcemia resulting from increased 
sensitivity of the CaSR to extracellular calcium [135]. 
7.3. Other Modulators 
 A potential drawback of most of the currently 
developed positive and negative allosteric modulators 
of the CaSR is that they are not fully selective for this 
receptor, since several allosteric modulators have been 
shown to activate or inhibit the closely related GPRC6A 
receptor [136, 137]. This receptor has recently been 
shown to mediate the response of cells to androgens in 
several tissues [138]. Thus, the non-selective 
modulation of GPRC6A signaling through allosteric 
modulators may cause several unwanted side-effects. 
Therefore, a new strategy should be undertaken to 
provide drugs exclusively targeting the CaSR. 
Recently, it was shown that the CaSR and GPRC6A 
share similar, but not identical, binding pockets at the 
level of the allosteric binding site within the 7TM [137], 
which may allow the development of novel allosteric 
modulators with improved selectivity. In addition to 
allosteric modulators of CaSR binding the 7TM, 
allosteric modulators targeting the ECD of the receptor 
could be developed [24]. Additionally, monoclonal 
antibodies that specifically bind to lobe 2 of the human 
CaSR VFT and activate or inhibit the CaSR response 
to calcium have been described [139] and could be of 
potential use in the treatment of diseases for which 
calcimimetics and calcilytics, respectively, have been 
indicated. 
7.4. Targeted Modulators 
 Since the CaSR is expressed in a wide variety of 
tissues, the long-term use of CaSR modulators to treat 
diseases specific to one tissue may have unintended 
consequences in other tissues. Thus, the next 
refinement of CaSR-modulating drugs should include 
designs for tissue-specific delivery. As the CaSR can 
heterodimerize with other family C GPCRs [34, 35], 
The Calcium-Sensing Receptor as a Regulator of Cellular Fate Current Molecular Medicine,  2013, Vol. 13, No. 2     291 
one potential tissue-specific targeting strategy could 
include modulators with specificity for heterodimers 
expressed in particular tissues [140]. Further research 
determining the precise tissue distribution of unique 
CaSR heterodimers will be required. 
8. CONCLUDING REMARKS 
 Over the past decade, the CaSR has been identified 
as a novel molecular player in the determination of 
cellular fate with a fundamental impact on proliferation, 
apoptosis and differentiation in a diverse array of 
tissues [2-10]. The CaSR coordinates these activities 
through regulation of a myriad of signaling pathways, 
including EGFR signaling, MAPK cascades and E-
cadherin signaling [3, 36, 37, 47, 50-52, 62-64]. 
However, few studies have assessed the cell- or 
tissue-specificity of the cascades activated by 
engagement of the CaSR or determined the particular 
roles of the signaling cascades, leaving considerable 
room for discovery in this field. Tissue-specific 
signaling appears to be driven by the differential 
expression of splice variants, the heterodimerization 
with additional GPCRs, tissue specific interacting 
partners, the use of differential promoters, and 
translational regulation by miRNAs [3, 15, 16, 18-20, 
34, 36, 37, 81]. 
 The use of selective CaSR drugs, together with 
antisense and conditional gene knock-out technology, 
will certainly be of benefit in further unraveling the role 
of CaSR in cellular fate. Recent reports clearly point to 
a role for the CaSR as a regulator of early development 
and as a guardian of the homeostatic balance between 
proliferation and differentiation in adults [19, 68, 70, 71, 
73, 75, 89, 92]. The identification of CaSR mutations 
that cause FHH and hypocalcemia [93-98], and the 
recent discoveries implicating the dysregulation of 
CaSR signaling in many other diseases [99, 113-115, 
119-124], position the CaSR as a broad therapeutic 
target. Adverse side-effects will likely be a challenging 
issue in the putative use of CaSR-modulating agents 
for the treatment of such a broad range of tissue-
specific diseases; therefore, future studies should focus 
on the development of CaSR-modulating drugs with a 
higher selectivity for the CaSR and specificity for the 
tissue of interest. 
ABBREVIATIONS 
5’UTR = 5’ Untranslated region 
AA = Arachidonic acid 
AC = Adenylate cyclase 
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BAF-155 = BRG1-associated factor 155 
BATF = Basic leucine zipper transcription factor 
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Bcl-2 = B-cell lymphoma 2 
cAMP = Cyclic AMP 
CaSR = Calcium-sensing receptor 
CNS = Central nervous system 
cPLA2 = Cytosolic phospholipase A2 
DAG = Diacylglycerol 
ECD = Extracellular domain 
EGFR = Epidermal growth factor receptor 
Egr-1 = Early growth response factor 1 
ERK = Extracellular signal-regulated kinase 
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GABABR = Type B -aminobutyric acid receptor 
GPCR = G protein-coupled receptor 
IP3 = Inositol 1,4,5-trisphosphate 
JNK = Jun N-terminal Kinase 
MAPK = Mitogen-activated protein kinase 
MEK = MAPK kinase 
mGluR = Metabotropic glutamate receptor 
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PKC = Protein kinase C 
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